<DOC>
	<DOC>NCT00632125</DOC>
	<brief_summary>Cumulative follow-up with HX575 epoetin alfa to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 epoetin alfa i.v.</brief_summary>
	<brief_title>Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>CKD subjects with or without dialysis treatment Age over 18 years Subjects requiring i.v. ESA treatment Subjects likely to remain on i.v. ESA treatment for 6 months Provision of informed consent Systemic immunosuppressive medication or any other drugs known to adversely affect the hemoglobin level Known primary lack of efficacy (LOE), unexplained loss of effect to a recombinant erythropoietin product History of PRCA or aplastic anemia History of antierythropoietin antibodies Uncontrolled hypertension Pregnant woman or nursing mother Women of childbearing potential do not agree to maintain effective birth control during the study treatment period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>CKD subjects with or without dialysis treatment</keyword>
</DOC>